<b>Conclusion:</b> The available data indicated that ankylosing spondylitis patients who received tumor necrosis factor alpha inhibitors had no significantly increased risks of serious adverse events when compared with the placebo group. The gene discussed is TNF; the disease is ankylosing spondylitis.